Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517483 | 0.85 | MAOA (0.67) | MAOAMAOBACHECYP2D6PPARG | |
| SCHEMBL1149879 | 0.85 | PTGER4 (0.67) | PTGER4CNR2MEN1KMT2AHPGD | |
| SCHEMBL2721051 | 0.83 | MAOA (0.59) | MAOAMAOBACHECYP2D6PPARG | |
| SCHEMBL12464615 | 0.82 | MAOA (0.63) | MAOAMAOBACHECYP2D6PPARG | |
| SCHEMBL17502355 | 0.82 | MAOA (0.78) | MAOAMAOBACHECYP2D6IDO1 | |
| SCHEMBL17502362 | 0.81 | MAOA (0.81) | MAOAMAOBACHECYP2D6IDO1 | |
| SCHEMBL17517489 | 0.81 | MAOA (0.81) | MAOAMAOBACHECYP2D6IDO1 | |
| SCHEMBL17502364 | 0.81 | MAOA (0.81) | MAOAMAOBACHECYP2D6IDO1 | |
| SCHEMBL17502374 | 0.81 | MAOA (0.81) | MAOAMAOBACHECYP2D6IDO1 | |
| SCHEMBL2216201 | 0.80 | MAOA (0.65) | MAOAMAOBACHECYP2D6PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125812-B2 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9107914-B2 | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9107914-B2 | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2519238-B1 | BETA-CARBOLINES FOR THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| EP-2125812-B1 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| WO-2008104161-A1 | ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD. (DE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | CBFB, ADRA2B, SLC6A12 | MAOA 2170/4885MAOB 329/4885ACHE 576/4885 |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | MAOA 130/4885MAOB 48/4885ACHE 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.